Intrarosa (U.S. Commercial Rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Intrarosa (U.S. Commercial Rights) General Information

Description

Rights to a steroidal drug intended for the treatment of moderate to severe dyspareunia. The drug is used to treat painful sexual intercourse for women after menopause.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • Waltham, MA 02451
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Corporate Office
  • Waltham, MA 02451
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intrarosa (U.S. Commercial Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Intrarosa (U.S. Commercial Rights)‘s full profile, request access.

Request a free trial

Intrarosa (U.S. Commercial Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Intrarosa (U.S. Commercial Rights)‘s full profile, request access.

Request a free trial

Intrarosa (U.S. Commercial Rights) FAQs

  • Where is Intrarosa (U.S. Commercial Rights) headquartered?

    Intrarosa (U.S. Commercial Rights) is headquartered in Waltham, MA.

  • What industry is Intrarosa (U.S. Commercial Rights) in?

    Intrarosa (U.S. Commercial Rights)’s primary industry is Buildings and Property.

  • Is Intrarosa (U.S. Commercial Rights) a private or public company?

    Intrarosa (U.S. Commercial Rights) is a Private company.

  • What is the current valuation of Intrarosa (U.S. Commercial Rights)?

    The current valuation of Intrarosa (U.S. Commercial Rights) is .

  • What is Intrarosa (U.S. Commercial Rights)’s current revenue?

    The current revenue for Intrarosa (U.S. Commercial Rights) is .

  • Who are Intrarosa (U.S. Commercial Rights)’s investors?

    AMAG Pharmaceuticals has invested in Intrarosa (U.S. Commercial Rights).

  • When was Intrarosa (U.S. Commercial Rights) acquired?

    Intrarosa (U.S. Commercial Rights) was acquired on 21-May-2020.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process